Organic Active Ingredients TRIZ Cases

Prebiotic gel encapsulates insoluble dietary fiber to adsorb alcohol and pesticides, preventing their absorption by the body.

Pairing Cbl-b inhibitors with TLR agonists overcomes insufficient anti-tumor efficacy from single-agent therapy.

Vibrating delivery device deposits imageable microcapsules to reduce systemic adverse effects.

Administering inhaled chelating agents to bind zinc and iron ions, reducing matrix metalloproteinase activity and reactive oxygen species.

Formula I compounds target hepatitis C virus activity while reducing toxicity and overcoming viral resistance.

Novel adenosine analogs inhibit methyltransferase activity via local quality design, resolving selectivity trade-offs in cancer treatment.

Administering ROR-1 antagonists alongside chemotherapy reduces ROR1-dependent signaling in chemoresistant breast cancer, inhibiting self-renewal and metastasis.

Trehalose replaces ineffective conventional agents to suppress vascular thickening and prevent ischemia complications.

Imine-mediated coupling grafts spacer arms onto active principles, reducing material loss and improving synthesis efficiency.

Administering a PKC inhibitor prior to a cytotoxic agent sensitizes cancer and autoimmune cells, reducing drug-resistant clones and side effects.

A bistable member switches between open and closed states to control drug diffusion from an implantable reservoir.

Mevidalen treats hallucinations and dementia-related psychosis by enhancing D1 receptor activity while avoiding adverse cardiovascular effects.

Targeting upstream regulators IRF1 and CMPK2 inhibits NLRP3 inflammasome activation, addressing ineffective current strategies.

Oxabicyclo[2.2.2]octane morphinans target peripheral opioid receptors to deliver analgesia.

An oil-in-oil emulsion delivers sustained lubrication via polysaccharide encapsulation, eliminating occlusive effects and mechanical irritation.

Novel nitrogen heterocycles target P2Y12 receptors to reduce thrombosis risk while managing structural complexity.

Amphotericin B and cholesterol complex permeabilizes apical membranes to restore bicarbonate transport.

Cellulose-based oral dosage form maintains comparable bioavailability across fed and fasting states, resolving inconsistent therapeutic effects.

Butylidenephthalide compounds inhibit excessive autophagy in motor neurons, addressing ineffective existing treatments that fail to prevent neuronal death.

Gene-edited hematopoietic cells resist anti-CD33 therapy, preventing noncancerous cell depletion and enabling reliable system repopulation.

Profiles HDAC expression ratios to identify patients likely to benefit from combination immunotherapy, addressing limited solid tumor response rates.

Octreotide-modified liposomes encapsulate irinotecan to selectively bind somatostatin receptors on tumor cells.

Novel tricyclic sulfonamides inhibit MetAP2 to lower body weight without the relapse rates or side effects of traditional pharmacotherapies.

Sustained-release scaffolds reduce inflammation and avoid surgery risks by delivering drugs directly to sinus tissue.

Inhaled spray-dried MOFs target pulmonary infections directly, bypassing systemic circulation to overcome drug resistance and shorten treatment duration.

A standardized tRNA effector molecule composition uses affinity-based purification to isolate high-purity therapeutic agents from mammalian host cells.

A synbiotic composition combines specific probiotic strains with prebiotic substrates to enhance gut microbiota diversity.

Replacing spCas9 with smaller SluCas9 enables genome editing within one AAV vector, reducing manufacturing complexity while maintaining high editing efficiency.

Inhibiting the PRC2 complex via EED or EZH2 modulators reduces BCL11A expression, increasing fetal hemoglobin production for sickle cell treatment.

Fc-fused IDUA crosses the blood-brain barrier to treat mucopolysaccharidosis type 1.

Glyceryltriacetate stabilizes microtubules and increases acetate levels to address insufficient therapeutic effects from limited preclinical treatments.

Adeno-associated viral vector delivers arginase 1 to hepatocytes, preventing dysmyelination and restoring myelinated axon density in arginase deficiency.

Steroidal selective androgen receptor modulators utilize specific 13-position side chains to achieve tissue-specific receptor activity.

Hyaluronan conjugates link sex hormones to hyaluronic acid, improving cognitive function while reducing side effects.

Dual orexin receptor antagonists improve sleep quality and reduce obesity risks while lowering toxicity compared to existing treatments.

Citric acid inhibits terconazole crystallization in water, maintaining stable solutions that release over 90% of the drug within five hours.

Covalent dimerization of phenolic compounds resists presystemic metabolism, avoiding central adverse effects while maintaining receptor pharmacology.

A composition of emblica, fucus, and chebula extracts induces mitochondrial biogenesis to treat viral infection symptoms.

Sotorasib formulations balance disintegration time and tensile strength using specific excipient ratios for effective KRAS G12C inhibition.

Sequential polyol esterification prevents skin penetration and irritation by avoiding free radical reactions.

Morphinan compounds modulate mu-opioid receptors to manage severe pain while minimizing respiratory depression risks.

Castanea sativa extracts inhibit agr quorum sensing in Staphylococcus aureus, reducing virulence without triggering antibiotic resistance development.

Citrate-based elastic biodegradable polymers combined with aniline tetramer create compounds enabling precise dual-modal imaging.

Statistical models predict disease remission by combining drug clearance estimates with genetic markers to guide personalized treatment regimens.

Indole-3-propionic acid salts stabilize S-adenosyl-L-methionine, eliminating gastrointestinal discomfort and enabling ambient storage.

Functionalized lactone compounds resolve receptor selectivity contradictions by targeting 5-HT7 receptors with high specificity for CNS and non-CNS indications.

Crystalline forms and salts of MCL-1 inhibitors resolve amorphous instability for manufacturing.